Welcome to the e-CCO Library!

OP37: Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. J. Sandborn*1, B. E. Sands2, R. Panaccione3, C. D. O’Brien4, H. Zhang4, J. Johanns4, L. Peyrin-Biroulet5, G. Van Assche6, S. Danese7, S. R. Targan8, M. T. Abreu9, T. Hisamatsu10, P. Szapary4, C. Marano4

Created: Friday, 22 February 2019, 9:41 AM
OP37: Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chaparro, M.(1)*;García Donday, M.(1);Riestra, S.(2);Lucendo, A.J.(3);Benítez, J.M.(4);Navarro-Llavat, M.(5);Barrio, J.(6);Morales-Alvarado, V.J.(7);Rivero, M.(8);Busquets, D.(9);Leo Carnerero, E.(10);Merino Ochoa, O.(11);Nantes Castillejo, O.(12);Navarro, P.(13);Van Domselaar, M.(14);Gutiérrez Casbas, A.(15);Alonso-Abreu, I.(16);Mejuto, R.(17);Fernández Salazar, L.(18);Iborra, M.(19); Martín-Arranz, M.D.(20); Pineda, J.R.(21); Sampedro, M.J.(22);Serra Nilsson, K.(23);Bouhmidi Assakali, A.(24);Batista, L.(25);Muñoz Villafranca, C.(26);Rodríguez-Lago, I.(27); Ceballos Santos, D.S.(28);Guerra, I.(29);Mañosa, M.(30);Marín Jimenez, I.(31); Vera Mendoza, I.(32);Barreiro-de Acosta, M.(17);Domènech, E.(30);Esteve, M.(25);García-Sánchez, V.(4);Nos, P.(19);Panés, J.(33);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP37: Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study
Year: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Hibi, T.(2);Ritter, T.E.(3);Dinoso, J.B.(4);Hsieh, J.(4);Yun, C.(4);Zhang, J.(4);Zhao, S.(4);Loftus Jr, E.V.(5);Rogler, G.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
OP38 Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s disease: A multicentre randomised controlled trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Jongsma MSc1, M. Aardoom1, M. Cozijnsen1, M. van Pieterson1, T. de Meij2, O. Norbruis3, M. Groeneweg4, V. Wolters5, H. van Wering6, I. Hojsak7, K.L. Kolho8, T. Hummel9, J. Stapelbroek10, C. van der Feen11, P. Rheenen12, M. van Wijk2, S. Teklenburg-Roord3, J. Escher1, J. Samsom13, L. Ridder1

Created: Thursday, 30 January 2020, 10:12 AM
OP38: Developing a Cost-Effective Genomic Biomarker of Cancer Risk in Patients with Ulcerative Colitis using Low-Pass Whole Genome Sequencing of Unselected Endoscopic Biopsies: A Case-Control Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Al Bakir, I.(1);Curtius, K.(1);Smith, K.(1);Kopczynska, M.(1);Moorghen, M.(2);Hart, A.(3);Graham, T.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Geert. R. D’Haens*1, W. J. Sandborn2, M. Ferrante3, B. R. Bhandari4, E. Berliba5, T. Hibi6, J. Tuttle7, J. B. Canavan8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9

Created: Friday, 22 February 2019, 9:41 AM
OP38: Modulation of the septin cytoskeleton ameliorates intestinal fibrogenesis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Naydenov, N.(1);Le, T.H.N.(1);Lechuga Villarauz, S.(1);Elias, M.(1);West, G.(1);Czarnecki, D.(1);Plesec, T.(1);Ivanov, A.(1);Rieder, F.(2)*;
Created: Friday, 14 July 2023, 10:43 AM
OP38: Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials
Year: 2022
Source: ECCO'22
Authors: Sandborn, W.J.(1);D'Haens, G.R.(2);Sands, B.E.(3);Panaccione, R.(4);Ng, S.C.(5);Lawendy, N.(6);Kulisek, N.(6);Guo, X.(6);Mundayat, R.(7);Su, C.(7);Panés, J.(8);
Created: Friday, 11 February 2022, 3:52 PM
OP39 Treatment of ulcerative colitis With AMT-101, a novel oral interleukin-10 immunomodulatory fusion biologic that traffics across the intestinal epithelium
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Mrsny1, B. Kanwar2, T. Mahmood3

Created: Thursday, 30 January 2020, 10:12 AM
OP39: Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ghosh, S.(1)*;Feagan, B.(2);Ott, E.(3);Gasink, C.(3);Marano, C.(4);Miao, Y.(4);Sandborn, W.(5);Danese, S.(6);Abreu, M.(7);Sands, B.(8);
Created: Friday, 14 July 2023, 10:43 AM
OP39: Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn’s Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Colombel, J.F.(2);Louis, E.(3);Ferrante, M.(4);Motoya, S.(5);Panaccione, R.(6);Torres, J.(7);Ungaro, R.C.(2);Kligys, K.(8);Kalabic, J.(9);Zambrano, J.(8);Zhang, Y.(8);D’Haens, G.R.(10);
Created: Friday, 11 February 2022, 3:52 PM
OP39: The effect of phenotype and genotype on the plasma proteome in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Bourgonje, A.R.(1);Hu, S.(1);Spekhorst, L.M.(1);Zhernakova, D.V.(2);Vich Vila, A.(1);Li, Y.(1);Voskuil, M.D.(1);van Berkel, L.A.(3);Bley Folly, B.(3);Charrout, M.(4);Mahfouz, A.(4);Reinders, M.J.T.(4);van Heck, J.I.P.(5);Joosten, L.A.B.(5);Visschedijk, M.C.(1);van Dullemen, H.M.(1);Faber, K.N.(1);Samsom, J.N.(3);Festen, E.A.M.(1);Dijkstra, G.(1);Weersma, R.K.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP40 A core transferable microbiota in responders to faecal microbiota transplant for ulcerative colitis shape mucosal T-cell immunity
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Gogokhia1, S. Lima1, M. Viladomiu1, Y. Gerardin2, C. Crawford1, V. Jacob1, E. Scherl1, M. Rosenthal3, S.E. Brown3, J. Hambor3, R. LONGMAN1

Created: Thursday, 30 January 2020, 10:12 AM
OP40: Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn’s Disease patients in the STARDUST trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Vermeire, S.(2);Dignass, A.(3);Panés, J.(4);D'Haens, G.(5);Magro, F.(6,7);Le Bars, M.(8);Nazar, M.(9);Lahaye, M.(10);Ni, L.(11);Bravatà, I.(12);Gaya, D.R.(13);Peyrin-Biroulet, L.(14)
Created: Wednesday, 2 June 2021, 4:12 PM
OP40: Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
Year: 2022
Source: ECCO'22
Authors: Bossuyt, P.(1);Bresso, F.(2);Dubinsky, M.(3);Ha, C.(4);Siegel, C.(5);Zambrano, J.(6);Kligys, K.(6);Kalabic, J.(6);Zhang, Y.(6);Panaccione, R.(7);
Created: Friday, 11 February 2022, 3:52 PM
OP40: PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results
Year: 2023
Source: ECCO’23 Copenhagen
Authors: B. Sands*(1), L. Peyrin-Biroulet(2), S. Danese(3), D.T. Rubin(4), S. Vermeire(5), O. Laurent(6), A. Luo(6), D. Nguyen(6), JD. Lu(6),A. Wiechowska-Kozlowska(7), J. Leszczyszyn(8), R. Kempinski(9), J. Kierkus(10), C. Ma(11), T. Ritter*(12), B.G. Feagan(13), S. Targan*(14)
Created: Friday, 14 July 2023, 10:43 AM
P0001: Single-cell profiling reveals distinct γδ T cell subsets with protective and pathogenic roles in Ulcerative Colitis
Year: 2025
Source: ECCO'25
Authors: Mayerx7x7x7 L.(1x7x7x72)*;Arnoldx7x7x7 J.(1x7x7x73);Reuterx7x7x7 N.(1);Pattekarx7x7x7 A.(2x7x7x74);Ohtanix7x7x7 T.(4);Bruderx7x7x7 K.(1);Ribeirox7x7x7 M.(5);Siwickix7x7x7 R.(5);Obwegsx7x7x7 D.(1x7x7x73);Stahlx7x7x7 E.(1);Kolterx7x7x7 J.(6x7x7x77);Mansoori Moghadamx7x7x7 Z.(6x7x7x77);Alaswadx7x7x7 A.(8);Lix7x7x7 Y.(8);Lewisx7x7x7 J.D.(2);Wux7x7x7 G.D.(2);Bewtrax7x7x7 M.(2);Tomovx7x7x7 V.T.(2);Bengschx7x7x7 B.(1x7x7x79);Thimmex7x7x7 R.(1);Hasselblattx7x7x7 P.(1);Picellix7x7x7 S.(5);Hofmannx7x7x7 M.(1);Sagarx7x7x7 S.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0002: Identification of Infliximab and Adalimumab -derived peptides using MHC class II antibody mediated immunopeptidomics and mass spectrometry: implications for drug re-design.
Year: 2025
Source: ECCO'25
Authors: Bedkex7x7x7 N.(1)*;Liaox7x7x7 H.(2);Nicastrix7x7x7 A.(3);Parkerx7x7x7 R.(3);Dzhonevax7x7x7 A.(3);Noblex7x7x7 A.(1);Al-Hillawix7x7x7 L.(1);Brainx7x7x7 O.(1);Satsangix7x7x7 J.(1);Ternettex7x7x7 N.(2);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0003: Differential Effects of JAK Inhibitors on Epithelial-Immune Interaction in Inflammatory Bowel Disease
Year: 2025
Source: ECCO'25
Authors: Floorx7x7x7 E.(1x7x7x72)*;van der Kooijx7x7x7 R.(2);van Wijkx7x7x7 F.(3);Oldenburgx7x7x7 B.(1);Vercoulenx7x7x7 Y.(2);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0004: Transcriptomic profiling as a tool for prediction of endoscopic inflammation in quiescent Crohn's Disease patients
Year: 2025
Source: ECCO'25
Authors: Meningherx7x7x7 T.(1)*;Finkelx7x7x7 O.(1);Nayshoolx7x7x7 O.(1);Fudimx7x7x7 E.(1);.Yavzorix7x7x7 M.(1);Picardx7x7x7 O.(1);Talan-Asherx7x7x7 A.(1);Yablekovitchx7x7x7 D.(1);kopylovx7x7x7 U.(1);Ben-Horinx7x7x7 S.(1);Ungarx7x7x7 B.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session